The first new drug for alcoholism treatment in 47 years was approved in January by the Food and Drug Administration. The drug, naltrexone hydrochloride, is marketed under the trade name ReVia. The Research Institute on Addictions conducted part of the clinical studies that preceded the drug's approval. Robert Whitney, M.D., Head of Medical Services in RIA's Clinical Research Center, is a physician who specializes in addiction treatment. He emphasized that the drug is not a magic bullet or a quick fix.
Naltrexone has a legitimate, but limited role.
On its own, it's of no value. For it to be useful, it must be accompanied by therapy. Clinical trials of naltrexone The Dupont Merck Pharmaceutical Company introduced naltrexone in 1984 under the trade name Trexan. It was originally approved for use in treating opiate addictions by helping addicts avoid relapse after they had been through withdrawal. After research suggested that it could benefit alcoholics, Dupont Merck sought approval for its use as part of alcoholism treatment.